Regeneron Pharmaceuticals (REGN) EPS & PE Ratio History
Current and historical earning per share (EPS) and price to earnings (PE) ratio for Regeneron Pharmaceuticals (REGN) over the last 10 years. The current PE ratio for Regeneron Pharmaceuticals as of August 18, 2017 is 43.98.
|Medical||Medical - Biomedical and Genetics||$49.742B||$4.860B|
|Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)|